Search research articles
Contact Us
Filters
Showing results (401-410 of 483) with videos related to
Page
of 49
Sort By:
Leukemia & Lymphoma
|
August 26, 2017
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)
José Falantes, Lisa Pleyer, Sylvain Thépot, et al.
Annals of Hematology
|
June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Ivan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Ejhaem
|
June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study
Heinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
European Urology Oncology
|
July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Niven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Pharmacology Research & Perspectives
|
June 3, 2023
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial
Noémie Mercier, Drifa Belhadi, Aline DeChanet, et al.
Blood
|
December 20, 2014
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study
Andreas Tiede, Robert Klamroth, Rüdiger E Scharf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 2, 2023
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Ana-Alicia Beltran-Bless, Mark J Clemons, Christian Fesl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2002
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5
Markus Sieber, Hans Tesch, Beate Pfistner, et al.
Oral Oncology
|
April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Danny Rischin, Kevin J Harrington, Richard Greil, et al.
Breast Care (Basel, Switzerland)
|
June 16, 2022
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Simon P Gampenrieder, Magdalena Pircher, Christian Fesl, et al.
Page
of 49
Search research articles
Search
Showing results (401-410 of 483) with videos related to
Sort By:
Page
of 49
Leukemia & Lymphoma
|
August 26, 2017
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)
José Falantes, Lisa Pleyer, Sylvain Thépot, et al.
Annals of Hematology
|
June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Ivan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Ejhaem
|
June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study
Heinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
European Urology Oncology
|
July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Niven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Pharmacology Research & Perspectives
|
June 3, 2023
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial
Noémie Mercier, Drifa Belhadi, Aline DeChanet, et al.
Blood
|
December 20, 2014
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study
Andreas Tiede, Robert Klamroth, Rüdiger E Scharf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 2, 2023
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Ana-Alicia Beltran-Bless, Mark J Clemons, Christian Fesl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2002
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5
Markus Sieber, Hans Tesch, Beate Pfistner, et al.
Oral Oncology
|
April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Danny Rischin, Kevin J Harrington, Richard Greil, et al.
Breast Care (Basel, Switzerland)
|
June 16, 2022
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Simon P Gampenrieder, Magdalena Pircher, Christian Fesl, et al.
Page
of 49